- Home
- PANW vs TMO Comparison
PANW vs TMO Comparison
Compare PANW & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | TMO |
|---|---|---|
| Founded | 2005 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4B | 223.0B |
| IPO Year | 2012 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PANW | TMO |
|---|---|---|
| Price | $329.67 | $612.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 39 | 18 |
| Target Price | $216.28 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 5.5M | 1.4M |
| Earning Date | 05-19-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | 0.79 | ★ 9.10 |
| Revenue | $2,273,100,000.00 | ★ $20,918,000,000.00 |
| Revenue This Year | $24.93 | $6.55 |
| Revenue Next Year | $19.97 | $5.11 |
| P/E Ratio | $424.18 | ★ $66.56 |
| Revenue Growth | ★ 29.04 | 14.47 |
| 52 Week Low | $139.57 | $435.27 |
| 52 Week High | $398.88 | $647.00 |
Technical Indicators
Market Signals| Indicator | PANW | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 51.66 |
| Support Level | $314.96 | $587.15 |
| Resistance Level | $374.77 | $645.50 |
| Average True Range (ATR) | 16.79 | 14.65 |
| MACD | -4.28 | -4.87 |
| Stochastic Oscillator | 25.13 | 15.60 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).